Does Sitagliptin (Januvia) cause weight loss? | Rounds Does Sitagliptin (Januvia) cause weight loss? | Rounds
Loading...

Does Sitagliptin (Januvia) cause weight loss?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: May 24, 2026 · View editorial policy

Weight Change With Sitagliptin (Januvia)

Dipeptidyl peptidase-4 (DPP-4) inhibitors are classified as weight-neutral therapies in adults with type 2 diabetes, and sitagliptin is a DPP-4 inhibitor. [1] DPP-4 inhibitors are not associated with clinically meaningful weight loss in randomized trial evidence aggregated in meta-analysis. [2]

Expected Direction and Magnitude of Weight Change

Sitagliptin is expected to produce no meaningful weight loss for most patients. [1] DPP-4 inhibitor therapy has been found to be weight neutral versus placebo in randomized trial evidence. [2]

Monotherapy Versus Combination Therapy

Weight neutrality with DPP-4 inhibitors is generally maintained when used as monotherapy. [2] Weight neutrality is also generally maintained when DPP-4 inhibitors are used as add-on therapy, since the expected weight effect is attributed to the drug class rather than to improved glycemia alone. [2]

Decision Framework for Diabetes Medications When Weight Loss Is the Priority

Weight-loss–associated antihyperglycemic therapies include glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP receptor agonists. [1] DPP-4 inhibitors such as sitagliptin are classified as weight neutral and are not selected specifically to promote weight loss. [1]

Evidence Supporting Weight Neutrality

A systematic review and meta-analysis of incretin-based therapies reported that GLP-1 analogues resulted in weight loss, while DPP-4 inhibitors were weight neutral. [2]

Treatment Targets and Goals Relevant to Weight Change

A weight-loss goal is better aligned with weight-loss–associated diabetes therapies rather than with DPP-4 inhibitors. [1] DPP-4 inhibitors are more appropriately used for glycemic control when weight loss is not an expected therapeutic effect. [1]

Common Pitfalls to Avoid

Assuming that improved glycemic control with sitagliptin will automatically cause weight loss is a common misconception. [2] Selecting sitagliptin as the primary agent specifically to achieve clinically meaningful weight loss is inconsistent with the class-level weight-effect profile. [1]

Related Questions